{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33486116",
  "DateCompleted": {
    "Year": "2021",
    "Month": "05",
    "Day": "24"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "01",
        "Day": "21"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.drudis.2021.01.010",
      "S1359-6446(21)00037-4"
    ],
    "Journal": {
      "ISSN": "1878-5832",
      "JournalIssue": {
        "Volume": "26",
        "Issue": "4",
        "PubDate": {
          "Year": "2021",
          "Month": "Apr"
        }
      },
      "Title": "Drug discovery today",
      "ISOAbbreviation": "Drug Discov Today"
    },
    "ArticleTitle": "Drugs acting on the renin-angiotensin system and SARS-CoV-2.",
    "Pagination": {
      "StartPage": "870",
      "EndPage": "874",
      "MedlinePgn": "870-874"
    },
    "Abstract": {
      "AbstractText": [
        "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing global Coronavirus 2019 (COVID-19) pandemic, resulting in thousands of deaths worldwide and representing a health challenge with few precedents in human history. Angiotensin-converting enzyme 2 (ACE-2) facilitates the access of SARS-CoV-2 to cells. Therapeutic agents acting on the renin-angiotensin system (RAS) might be able to modulate the concentration of ACE-2 and the various components of the system. Here, we discuss current pharmacological, molecular, and clinical evidence to investigate whether drugs acting on RAS with modulation of the ACE-2 concentration have added value in combating SARS-CoV-2 infection. We also highlight the possible deleterious action of the ACE/Ang-II/AT-1r axis and possible beneficial role of the ACE-2/Ang 1-7/MasR axis in acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2, discussing the possibility of addressing the various RAS components with drug treatments to improve clinical outcomes."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 Elsevier Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "USL Umbria 1, Pharmaceutical Department, Perugia, Italy."
          }
        ],
        "LastName": "Vitiello",
        "ForeName": "Antonio",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "USL Umbria 2, Pharmaceutical Department, Terni, Italy."
          }
        ],
        "LastName": "Pelliccia",
        "ForeName": "Chiara",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "USL Umbria 1, Pharmaceutical Department, Perugia, Italy. Electronic address: francesco.ferrara@uslumbria1.it."
          }
        ],
        "LastName": "Ferrara",
        "ForeName": "Francesco",
        "Initials": "F"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Drug Discov Today",
    "NlmUniqueID": "9604391",
    "ISSNLinking": "1359-6446"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "Angiotensin-Converting Enzyme 2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme 2"
    },
    {
      "QualifierName": [
        "metabolism",
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Renin-Angiotensin System"
    },
    {
      "QualifierName": [
        "drug effects",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Internalization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "The authors declare no conflict of interest."
}